Scientific Materials

Combination of a T cell activating therapy and anti-phosphatidylserine enhances anti-tumour immune responses in a HPV16 E7-expressing C3 tumour model

Brennan S. Dirk, Genevieve Weir, Tara Quinton, Olga Hrytsenko, Marianne M. Stanford

Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The SPiReL Study

Quantitative MRI cell tracking of immune cell recruitment to tumors and draining lymph nodes in response to anti-PD-1 and a DPX-based immunotherapy

Marie-Laurence Tremblay, Zoe O’Brien-Moran, James A. Rioux, Andrea Nuschke, Christa Davis, W. Martin Kast, Genevieve Weir, Marianne Stanford & Kimberly D. Brewer

Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab

Generation of highly activated, antigen-specific tumor-infiltrating CD8+ T cells induced by a novel T cell-targeted immunotherapy, Vila-Leahey A, MacKay A , Portales-Cervantes L, Weir GM , Merkx-Jacques A, Stanford MM

Vila-Leahey A, MacKay A , Portales-Cervantes L, Weir GM , Merkx-Jacques A, Stanford MM

T cell infiltration into tumors induced by DPX-Survivac combination immunotherapy demonstrated by PET/MR imaging in an orthotopic ovarian cancer model

DPX platform for Drug Delivery: Evaluation of lymph node-targeted delivery of immunomodulatory agents in DPX

Evaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein

Torrey HL, Kaliaperumal V, Bramhecha Y, Weir GM, Falsey AR, Walsh EE, Langley JM, Schepens B, Saelens X, Stanford MM.

Infiltration of tumor by T cells following treatment with DPX-Survivac and intermittent low dose cyclophosphamide (CPA) leads to clinical responses in advanced recurrent ovarian cancer (OvCa) DPX-Survivac, a novel T cell immunotherapy, induces robust T cell responses in advanced ovarian cancer with significant anti-tumor efficacy